Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy

Pathology Research and Practice

Volumn 208, Issue 4, 2012, Pages 217-220

  Catteau, Xavier ^a   Simon, Philippe ^a   Noël, Jean Christophe ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Calcification; Ductal carcinoma in situ; Invasion; Sentinel lymph node biopsy

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CALCIFICATION; BREAST CANCER; BREAST EPITHELIUM; BREAST HYPERPLASIA; BREAST NECROSIS; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MICROMETASTASIS; NEEDLE BIOPSY; PARTIAL MASTECTOMY; PREDICTION; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CALCINOSIS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HYPERPLASIA; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; NECROSIS; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SPECIMEN HANDLING;

EID: 84859444319     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.02.003     Document Type: Article

References (25)

1. Andersson I., Aspegren K., Janzon L., Landberg T., Lindholm K., Linell F., et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ 1988, 297:943-948.
2. Bagnall M.J., Evans A.J., Wilson A.R., Pinder S.E., Denley H., Geraghty J.G., et al. Predicting invasion in mammographically detected microcalcification. Clin. Radiol. 2001, 56:828-832.
3. Burstein H.J., Polyak K., Wong J.S., Lester S.C., Kaelin C.M. Ductal carcinoma in situ of the breast. N. Engl. J. Med. 2004, 350:1430-1441.
4. Cox C.E., Nguyen K., Gray R.J., Salud C., Ku N.N., Dupont E., et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?. Am. Surg. 2001, 67:513-519.
5. Dillon M.F., McDermott E.W., Quinn C.M., O'Doherty A., O'Higgins N., Hill A.D. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J. Surg. Oncol. 2006, 93:559-563.
6. Ernster V.L., Barclay J., Kerlikowske K., Wilkie H., Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch. Intern. Med. 2000, 160:953-958.
7. Fleissig A., Fallowfield L.J., Langridge C.I., Johnson L., Newcombe R.G., Dixon J.M., et al. Post-operative arm morbidity and quality of life Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res. Treat. 2006, 95:279-293.
8. Goyal A., Douglas-Jones A., Monypenny I., Sweetland H., Stevens G., Mansel R.E. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? Analysis of 587 cases. Breast Cancer Res. Treat. 2006, 3:311-314.
9. Han J.S., Molberg K.H., Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J. 2011, 17:223-229.
10. Hill A.D., Tran K.N., Akhurst T., Yeung H., Yeh S.D., Rosen P.P., et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann. Surg. 1999, 229:528-535.
11. Hung W.K., Ying M., Chan M., Mak K.L., Chan L.K. The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ. Breast Cancer 2010, 17:276-280.
12. Intra M., Veronesi P., Mazzarol G., Galimberti V., Luini A., Sacchini V., et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch. Surg. 2003, 138:309-313.
13. Kelemen P.R. Comprehensive review of sentinel lymphadenectomy in breast cancer. Clin. Breast Cancer 2000, 1:111-125.
14. Klauber-DeMore N., Tan L.K., Liberman L., Kaptain S., Fey J., Borgen P., et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in situ and ductal carcinoma-in situ with microinvasion?. Ann. Surg. Oncol. 2000, 7:636-642.
15. Lagios M.D., Westdahl P.R., Margolin F.R., Rose M.R. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982, 50:1309-1314.
16. Pendas S., Dauway E., Giuliano R., Ku N., Cox C.E., Reintgen D.S. Sentinel node biopsy in ductal carcinoma in situ patients. Ann. Surg. Oncol. 2000, 7:15-20.
17. Pendas S., Jakub J., Giuliano R., Gardner M., Swor G.B., Reintgen D.S. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control 2004, 11:231-235.
18. Rutstein L.A., Johnson R.R., Poller W.R., Dabbs D., Groblewski J., Rakitt T., et al. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J. 2007, 13:251-257.
19. Schwartz G.F., Giuliano A.E., Veronesi U., Consensus Conference Committee Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002, 94:2542-2551.
20. Silverstein M.J., Gierson E.D., Waisman J.R., Senofsky G.M., Colburn W.J., Gamagami P. Axillary lymph node dissection for T1a breast carcinoma Is it indicated?. Cancer 1994, 73:664-667.
21. Silverstein M.J., Waisman J.R., Gamagami P., Gierson E.D., Colburn W.J., Rosser R.J., et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990, 66:102-108.
22. Strickland A.H., Beechey-Newman N., Steer C.B., Harper P.G. Sentinel node biopsy: an in depth appraisal. Crit. Rev. Oncol. Hematol. 2002, 44:45-70.
23. van la Parra R.F., Ernst M.F., Barneveld P.C., Broekman J.M., Rutten M.J., Bosscha K. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast. Eur. J. Surg. Oncol. 2008, 34:631-635.
24. Yen T.W., Hunt K.K., Ross M.I., Mirza N.Q., Babiera G.V., Meric-Bernstam F., et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J. Am. Coll. Surg. 2005, 200:516-526.
25. Yi M., Krishnamurthy S., Kuerer H.M., Meric-Bernstam F., Bedrosian I., Ross M.I., et al. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am. J. Surg. 2008, 196:81-87.